Diferencia entre revisiones de «Ticarcillin/Clavulanate»

Sin resumen de edición
(Add AntibioticDose SMW query table for dynamic indications by disease)
 
(No se muestra una edición intermedia de otro usuario)
Línea 19: Línea 19:
**First Dose:  
**First Dose:  
**Max: 18 g/day
**Max: 18 g/day
===Indications by Disease===
{{#ask: [[Has DrugName::Ticarcillin/Clavulanate]] [[Has Population::Adult]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}


==Pediatric Dosing==
==Pediatric Dosing==
'''Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)'''
'''Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)'''
===Indications by Disease===
{{#ask: [[Has DrugName::Ticarcillin/Clavulanate]] [[Has Population::Pediatric]]
|?Treats disease=Disease
|?Has Dose=Dose
|?Has Context=Context
|format=table
|limit=50
|mainlabel=-
|headers=show
|sort=Treats disease
}}
===General (≥3 Months)===
===General (≥3 Months)===
*'''<60 kg'''
*'''<60 kg'''
Línea 154: Línea 178:
| ||[[Acinetobacter sp.]]||I
| ||[[Acinetobacter sp.]]||I
|-
|-
| ||[[Pseudomonas aeruginosa]]||'''S'''
| ||[[Pseudomonas aeruginosa]]||'''[[Has Antipseudomonal::S]]'''
|-
|-
| ||[[Burkholderia cepacia]]||X1
| ||[[Burkholderia cepacia]]||X1

Revisión actual - 20:38 20 mar 2026

Brand Discontinued in U.S

General

  • Type: Anti-Pseudomonal Penicillin
  • Dosage Forms:
  • Common Trade Names: Timentin

Adult Dosing

Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)

General

  • <60 kg
    • 200-300mg ticarcillin/kg/day IV divided q4-6 hours
    • First Dose:
    • Max: 18 g/day
  • ≥60 kg
    • 3.1 g every 4-6 hours
    • First Dose:
    • Max: 18 g/day

Indications by Disease

DiseaseDoseContext
Diabetic foot infection3.1g IV q8hrsInpatient DFI
Orbital cellulitis3.1 g IV q4hInpatient
Peritonsillar abscess3.1 g IV QIDInpatient

Pediatric Dosing

Ticarcillin/clavulanate: each 3.1g dose contains 3g ticarcillin and 0.1g clavulanate (dosages written by ticarcillin component)

Indications by Disease

General (≥3 Months)

  • <60 kg
    • 200-300mg ticarcillin/kg/day IV divided q4-6 hours
    • First Dose: 50mg tiacarcillin/kg IV x 1
    • Max: 18g/day
  • ≥60 kg
    • 3.1 g q4-6 hours
    • Max: 18g/day

Special Populations

  • Pregnancy: B
  • Lactation: Use caution
  • Renal Dosing

Considerations for hemodialysis/peritoneal dialysis and CRRT patients NOT included below

    • Adult

Loading dose: IV: 3.1 g one dose, followed by maintenance dose based on creatinine clearance:

CrCl 30-60 mL/minute: 2 g of ticarcillin component every 4 hours

CrCl 10-30 mL/minute: 2 g of ticarcillin component every 8 hours

CrCl <10 mL/minute: 2 g of ticarcillin component every 12 hours

CrCl <10 mL/minute with concomitant hepatic dysfunction: 2 g of ticarcillin component every 24 hours

    • Pediatric

No dosing adjustments in manufacturer's label, clinical recommendations include:

GFR >30 mL/minute/1.73 m2: No adjustment required.

GFR 10-29 mL/minute/1.73 m2: 50 to 75 mg ticarcillin/kg every 8 hours

GFR <10 mL/minute/1.73 m2 (without concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 12 hours

GFR <10 mL/minute/1.73 m2 (with concomitant hepatic failure): 50 to 75 mg ticarcillin/kg every 24 hours

  • Hepatic Dosing
    • Adult

With concomitant renal dysfunction (Clcr <10 mL/minute): 2 g of ticarcillin component every 24 hours.

    • Pediatric

No specific pediatric recommendations, adjust if concomitant renal dysfunction

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: Ticarcillin: 1.1 hours; Clavulanic acid: 1.1 hours
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep I
Strep. anginosus gp S
Enterococcus faecalis I
Enterococcus faecium I
MSSA S
MRSA R
CA-MRSA R
Staph. Epidermidis I
C. jeikeium R
L. monocytogenes X2
Gram Negatives N. gonorrhoeae X2
N. meningitidis S
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos S
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii S
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. I
Pseudomonas aeruginosa S
Burkholderia cepacia X1
Stenotrophomonas maltophilia S
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp R
Mycoplasm pneumoniae R
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis S
Prevotella melaninogenica S
Clostridium difficile X1
Clostridium (not difficile) S
Fusobacterium necrophorum S
Peptostreptococcus sp. S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. ↑ Sanford Guide to Antimicrobial Therapy 2014

Dowell JA, Korth-Bradley J, Milisci M, et al, "Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment," J Clin Pharmacol, 2001, 41:979-86 PMID: 11549103

Obtenido de «https://www.wikem.org/w/index.php?title=Ticarcillin/Clavulanate&oldid=387297»